Humanigen, Inc.

OTCPK:HGEN.Q Stock Report

Market Cap: US$119.0

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Humanigen Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Cameron Durrant

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure8.3yrs
CEO ownershipn/a
Management average tenureno data
Board average tenure7.5yrs

Recent management updates

Recent updates

Humanigen GAAP EPS of -$0.43 misses by $0.11, revenue of $1.04M beats by $0.69M

Aug 12

Humanigen plunges 57% as trial for COVID-19 therapy fails

Jul 13

Humanigen jumps over 10% after peer-reviewed data on COVID-19 therapy

Jul 06

Humanigen (NASDAQ:HGEN) Has Debt But No Earnings; Should You Worry?

Oct 30
Humanigen (NASDAQ:HGEN) Has Debt But No Earnings; Should You Worry?

Health Check: How Prudently Does Humanigen (NASDAQ:HGEN) Use Debt?

Jul 14
Health Check: How Prudently Does Humanigen (NASDAQ:HGEN) Use Debt?

Humanigen begins rolling submission for lenzilumab in COVID-19 in U.K.

Jun 14

Humanigen submits lenzilumab COVID-19 EUA application to FDA

May 28

Humanigen is on the rise after publication of Phase 3 data for COVID-19 therapy

May 05

Humanigen, Inc.'s (NASDAQ:HGEN) Intrinsic Value Is Potentially 61% Above Its Share Price

May 05
Humanigen, Inc.'s (NASDAQ:HGEN) Intrinsic Value Is Potentially 61% Above Its Share Price

We Might See A Profit From Humanigen, Inc. (NASDAQ:HGEN) Soon

Mar 31
We Might See A Profit From Humanigen, Inc. (NASDAQ:HGEN) Soon

Is Humanigen, Inc. (NASDAQ:HGEN) Popular Amongst Institutions?

Feb 26
Is Humanigen, Inc. (NASDAQ:HGEN) Popular Amongst Institutions?

Enrollment completed in Humanigen's late-stage study of lenzilumab in COVID-19

Jan 29

Humanigen partners with EVERSANA for launch and commercialization of Lenzilumab for COVID-19 treatment

Jan 11

We Think Humanigen (NASDAQ:HGEN) Can Afford To Drive Business Growth

Jan 04
We Think Humanigen (NASDAQ:HGEN) Can Afford To Drive Business Growth

Humanigen secures new U.S. patent for lenzilumab

Dec 28

Enrollment completed in Humanigen's early-stage ifabotuzumab study in glioblastoma multiforme

Dec 17

Humanigen EPS misses by $0.16

Nov 11

Humanigen up 7% on partnership with U.S. government to advance lenzilumab for COVID-19

Nov 06

Humanigen executes lenzilumab licensing deal in Asia for COVID-19

Nov 03

Humanigen Dosing Phase 3  Covid Patients, And Other News: The Good, Bad And Ugly Of Biopharma

Nov 01

Dosing underway in lenzilumab late-stage study in COVID-19

Oct 30

Dosing underway in mid-stage study of Humanigen's lenzilumab in COVID-19

Oct 29

CEO Compensation Analysis

How has Cameron Durrant's remuneration changed compared to Humanigen's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2023n/an/a

-US$54m

Dec 31 2022US$1mUS$640k

-US$71m

Sep 30 2022n/an/a

-US$109m

Jun 30 2022n/an/a

-US$152m

Mar 31 2022n/an/a

-US$192m

Dec 31 2021US$10mUS$640k

-US$237m

Sep 30 2021n/an/a

-US$235m

Jun 30 2021n/an/a

-US$199m

Mar 31 2021n/an/a

-US$153m

Dec 31 2020US$2mUS$600k

-US$90m

Sep 30 2020n/an/a

-US$59m

Jun 30 2020n/an/a

-US$31m

Mar 31 2020n/an/a

-US$10m

Dec 31 2019US$785kUS$600k

-US$10m

Sep 30 2019n/an/a

-US$10m

Jun 30 2019n/an/a

-US$10m

Mar 31 2019n/an/a

-US$9m

Dec 31 2018US$4mUS$600k

-US$12m

Sep 30 2018n/an/a

-US$13m

Jun 30 2018n/an/a

-US$18m

Mar 31 2018n/an/a

-US$22m

Dec 31 2017US$790kUS$600k

-US$22m

Compensation vs Market: Insufficient data to establish whether Cameron's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Cameron's compensation has been consistent with company performance over the past year.

CEO

Cameron Durrant (64 yo)

8.3yrs

Tenure

US$1,099,058

Compensation

Dr. Cameron Durrant, MD, MBA, DRCOG, DIPCH, MRCGP, FLSW, has been Chairman of Humanigen, Inc. since January 2016. Dr. Durrant has been Chief Executive Officer at Humanigen, Inc. since March 2016 and has be...

Board Members

NamePositionTenureCompensationOwnership
Cameron Durrant
Chairman8.5yrsUS$1.10mno data
Dale Chappell
Chief Scientific Officer & Director3.4yrsUS$661.96k0%
$ 0
Rainer Boehm
Independent Director6.4yrsUS$81.20k0.071%
$ 0.08
Ronald Barliant
Independent Director8.5yrsUS$61.60k0.075%
$ 0.09

7.5yrs

Average Tenure

64yo

Average Age

Experienced Board: HGEN.Q's board of directors are considered experienced (7.5 years average tenure).